[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=177767ec3966ad8512e7af6e554394b3f108e8b96a64e13c4c40c899f52fe917",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760373900,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "id": 137083654,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=177767ec3966ad8512e7af6e554394b3f108e8b96a64e13c4c40c899f52fe917"
    }
  },
  {
    "ts": null,
    "headline": "Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade)",
    "summary": "Celldex Therapeutics, Inc. surges on barzolvolimab progress in chronic urticaria. Explore trial updates, risks, and valuation insights. Click for my CLDX update.",
    "url": "https://finnhub.io/api/news?id=729225defb2fba94b10d7ab0343eb5c48bb47f5c865a0ba7cf415ccf17027861",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760366133,
      "headline": "Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade)",
      "id": 137068943,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2226759250/image_2226759250.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Celldex Therapeutics, Inc. surges on barzolvolimab progress in chronic urticaria. Explore trial updates, risks, and valuation insights. Click for my CLDX update.",
      "url": "https://finnhub.io/api/news?id=729225defb2fba94b10d7ab0343eb5c48bb47f5c865a0ba7cf415ccf17027861"
    }
  },
  {
    "ts": null,
    "headline": "REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss",
    "summary": "Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.",
    "url": "https://finnhub.io/api/news?id=ce73ccf84c078183f6b97317d39ed1e2d7411bc626cc4724d51266411c9d48ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760364120,
      "headline": "REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss",
      "id": 137068882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.",
      "url": "https://finnhub.io/api/news?id=ce73ccf84c078183f6b97317d39ed1e2d7411bc626cc4724d51266411c9d48ac"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top stocks to buy in Michael Burry’s stock portfolio. On October 6, the company announced it is poised to incur an $83 million in-process research and development (IPR&D) charge. The charge is related to an $80 million up-front payment made to Hansoh Pharmaceuticals Group Company Limited as […]",
    "url": "https://finnhub.io/api/news?id=bec03d95b50e92f853dcfbf0679dfd533be4ed07109d6113d6d5fa3829da2739",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760363055,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge",
      "id": 137068883,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top stocks to buy in Michael Burry’s stock portfolio. On October 6, the company announced it is poised to incur an $83 million in-process research and development (IPR&D) charge. The charge is related to an $80 million up-front payment made to Hansoh Pharmaceuticals Group Company Limited as […]",
      "url": "https://finnhub.io/api/news?id=bec03d95b50e92f853dcfbf0679dfd533be4ed07109d6113d6d5fa3829da2739"
    }
  }
]